ARCHIVES

As FDA Weighs its Options on Morcellation, Debate Erupts Over Harvard Device Study

This article is from The Cancer Letter archive.

Vol. 40 No. 44 | November 21, 2014

Download PDF Visit The Full Archive

Related Articles

Single-Agent Phase III Trial Comparing Vectibix to Erbitux Meets Primary Endpoint

May 31, 2013

NCAB Ponders Patient Accrual Problems, Members Irate Over System That Discourages Participation

February 19, 1988

Toxicology Program Board To Review Nine Substances.

January 14, 2000

AVEO’s Tizozanib Fails in Colorectal Cancer

January 10, 2014

IOM Recommends FDA Consolidate Each Drug’s Lifetime History

May 4, 2012

DCT Board Insists On Being Heard In Development Of CCOP Guidelines

February 19, 1982